Topas Therapeutics
Business Services · Germany · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Falkenried 88, Hamburg, Hamburg, 20251, ...Phone Number
+49 40302089010Website
www.topas-therapeutics.comRevenue
$6 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Topas Therapeutics
Topas Therapeutics is pioneering a novel approach to establish immune tolerance in autoimmune and immune-mediated diseases through its proprietary antigen-specific nanoparticle technology. The company's lead candidate, TPM502, has shown promising results in a Phase 2a clinical trial for celiac disease and is preparing for a global Phase 2b trial. Their Topas Particle Conjugates target liver sinusoidal endothelial cells to induce anti-inflammatory immune responses and promote T cell tolerance. By addressing the underlying mechanisms of autoimmune diseases, Topas aims to provide significant therapeutic benefits to patients with limited treatment options.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Topas Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Topas Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Topas Therapeutics
Product Launch: Get notified when Topas Therapeutics launches new products
Check out if Topas Therapeutics is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Topas Therapeutics recently announced quarterly report
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Topas Therapeutics has new funding data
Topas Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Topas Therapeutics had a recent Job posting/layoffs
Recommended Actions
Find VP level buyers at Topas Therapeutics
Find 3 more new buyers
Company Profile Activity
Activity Insights
Topas Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Topas Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Topas Therapeutics.
Topas Therapeutics financials insights
Gather financial insights about Topas Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Series A
$16.5M
2020
Series B
$26M
Topas Therapeutics Tech Stack
A closer look at the technologies used by Topas Therapeutics
See more technologies
Most Recent Scoops
New Hire
Executive Move
Executive Moves, New Hire
Promotion
Executive Move
New Hire
Executive Move
Funding
Left Company
Executive Move
Topas Therapeutics News & Media
Topas Therapeutics Announces Presentation of Phase 2a Data for TPM502 in Celiac Disease at Digestive Disease Week® 2025 in San Diego
HAMBURG, Germany--(BUSINESS WIRE)--Topas Therapeutics today announced that it will present clinical Phase 2a data on its lead candidate, TPM502, in celiac disease patients at the upcoming Digestive Disease Week® (DDW) 2025, held from May 3–6, 2025, in San Diego, CA. TPM502 comprises a tolerizing nanoparticle mixture that carries the crucial gluten epitopes for HLA-DQ2.5, present in most celiac disease patients. In October of last year, the company announced positive topline results from its PhaTopas Therapeutics Publishes Foundational Data Demonstrating Tolerance Induction by its Proprietary Nanoparticle Platform in Frontiers in Immunology
HAMBURG, Germany--(BUSINESS WIRE)--Topas Therapeutics today announced the publication of data highlighting the ability of its proprietary antigen-coupled nanoparticles’ to achieve tolerance induction in relevant autoimmune disease models, under the title “Nanoparticle Platform Preferentially Targeting Liver Sinusoidal Endothelial Cells Induces Tolerance in CD4+ T Cell-Mediated Disease Models” in the journal Frontiers in Immunology. The Topas platform consists of Topas Particles (TPs), that servTopas Therapeutics Announces Positive Topline Results from Phase 2a Trial Evaluating TPM502 in Patients with Celiac Disease
HAMBURG, Germany--(BUSINESS WIRE)--Topas Therapeutics today announced positive topline results from its Phase 2a trial evaluating lead candidate, TPM502, in patients with celiac disease. The study data serves as the first clinical proof of concept for Topas’ proprietary nanoparticle platform and its potential to induce targeted, antigen-specific tolerogenic effects. The international, multi-center, double-blind, randomized, placebo-controlled Phase 2a trial (NCT05660109) was initiated in 2023 tTopas Therapeutics Appoints Hugo Fry as CEO
HAMBURG, Germany--(BUSINESS WIRE)--Topas Therapeutics, a clinical-stage biotech company developing novel antigen-specific immune tolerance therapies to treat autoimmune disorders, announced today the appointment of Hugo Fry as its new Chief Executive Officer. Bringing three decades of experience including senior management and executive roles at both large pharmaceutical and innovative biotechnology companies, Hugo has a significant track record in leading companies from early research and deve
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Topas Therapeutics
Sign Up For FreeTo access detailed company insights
Topas Therapeutics is pioneering a novel approach to establish immune tolerance in autoimmune and immune-mediated diseases through its proprietary antigen-specific nanoparticle technology. The company's lead candidate, TPM502, has shown promising results in a Phase 2a clinical trial for celiac disease and is preparing for a global Phase 2b trial. T... Read More
